Astrazeneca Completes Enrolment In Second Pivotal Study For Vandetanib (Zactima (Tm) ) In Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca announced that it has completed enrolment in a further two pivotal Phase III trials for investigational once-daily oral anti-cancer drug, vandetanib. Results from these two Phase III studies, ZODIAC and ZEAL, are expected later this year.

More: continued here

Filed under: Lung Cancer on March 14th, 2008